Citius Pharmaceuticals, Inc. CTXR PHARMA
Company Overview
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -53.09% |
| 6 Months: | -28.43% |
| 3 Months: | +1.95% |
| 1 Month: | -11.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 67.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTXR Citius Pharmaceuticals, Inc. PHARMA | 0.60 | -0.34 | $16.47M | 0.00% | -44.79% | -81.09% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.94M | 1.67M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.15M | 1.34M |
| Operating Income | -9.34K | -3.44K | -499.19K | -49.83K | -1.30K | -878.90K | -608.91K | -773.73K | -1.24M | -671.61K | -2.13M | -2.78M | -2.54M | -2.26M | -3.24M | -4.87M | -2.02M | -3.87M | -3.64M | -4.43M | -4.45M | -4.43M | -4.69M | -8.16M | -4.19M | -5.98M | -9.26M | -7.59M | -8.92M | -7.25M | -10.69M | -8.67M | -9.34M | -10.97M | -10.63M | -10.04M | -11.26M | -8.79M | -9.02M | -32.19M |
| Net Income | -10.23K | -4.43K | -534.41K | -90.28K | -34.88K | -823.71K | -345.27K | -824.97K | -1.22M | -869.45K | -3.62M | -2.18M | -2.74M | -2.42M | -3.25M | -4.42M | -2.02M | -3.87M | -3.63M | -4.41M | -4.32M | -4.42M | -4.68M | -8.15M | -4.12M | -5.82M | -9.23M | -7.56M | -8.86M | -3.59M | -10.53M | -8.48M | 9.23M | -8.54M | -10.57M | -10.28M | -11.51M | - | - | - |
| Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.05 | -0.06 | -0.05 | -0.06 | -0.02 | -0.07 | -0.06 | -1.45 | -1.34 | -1.57 | -1.30 | -1.27 | -0.80 | -0.38 | -0.95 |
| R&D Expense | - | - | 437.40K | - | - | 477.12K | 282.24K | 415.53K | 829.16K | -200.30K | 381.12K | 1.41M | 859.91K | 190.65K | 606.52K | 3.44M | 778.86K | 2.11M | 1.70M | 2.77M | 2.66M | 2.02M | 2.64M | 6.19M | 1.55M | 2.20M | 5.46M | 3.45M | 4.89M | 3.45M | 4.73M | 3.76M | 2.62M | 3.61M | 2.76M | 2.13M | 3.77M | 1.62M | 1.60M | 1.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Dec 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | - | - | - | - | 50.00K | 75.00K | 90.00K | 90.00K | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.32M | 36.73M | 42.00M | 38.53M |
| Operating Income | - | -25.64K | -19.62K | -28.12K | -1.18M | -653.80K | -3.23M | -7.45M | -9.99M | -13.79M | -15.60M | -17.71M | - | -33.32M | -36.73M | -42.00M | -38.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.14M | -36.54M | -41.79M | -38.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 10.84K | 0 | - | - | 267.78K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.06M | -31.97M | -38.85M | -38.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 576.00K | 576.00K | 576.00K | 1.06M |
| Net Income | -15.50K | -26.34K | -22.01K | -31.37K | -1.29M | -737.73K | -2.90M | -8.30M | -10.38M | -12.54M | -15.56M | -17.55M | - | -33.64M | -32.54M | -39.14M | -37.43M |
| Diluted EPS | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | -5.75 | -5.57 | -5.97 | -3.38 |
| R&D Expense | - | - | - | - | 492.14K | 574 | 1.80M | 2.93M | 2.94M | 6.56M | 8.60M | 8.81M | 12.24M | 17.66M | 14.82M | 11.91M | 9.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2010 | Jun 2011 | Sep 2011 | Sep 2012 | Dec 2012 | Sep 2013 | Dec 2013 | Sep 2014 | Sep 2015 | Jun 2016 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Oct 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 2.50K | - | 212 | 135 | - | 0 | - | 1.56M | 741.54K | - | 21.95M | 24.42M | 31.05M | 36.75M | 43.77M | - | 142.43M | 114.00M | 103.61M | 116.65M | 130.94M |
| Total Equity | 2.50K | -23.84K | -23.84K | -45.85K | -1.61M | -14.69K | -2.90M | -741.93K | -635.21K | - | 16.77M | 21.95M | 30.64M | 27.15M | 33.67M | 33.67M | 132.18M | 102.83M | 90.83M | 70.08M | 67.55M |
| Cash & Equivalents | 0 | - | 212 | 135 | 41.66K | 0 | 54.39K | 1.55M | 676.14K | 1.63M | 294.35K | 3.20M | 9.18M | 7.89M | 13.86M | - | 70.07M | 41.71M | 26.48M | 3.25M | 4.25M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.59M | 10.10M | - | 9.65M | 10.57M | 12.18M | 42.55M | 53.41M |
| Current Liabilities | - | - | 24.05K | 45.98K | - | 14.69K | - | 2.30M | 1.38M | - | 5.18M | 2.47M | 3.18M | 4.61M | 4.10M | - | 3.98M | 4.53M | 5.78M | 35.81M | 44.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2011 | Sep 2012 | Sep 2013 | Dec 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.78K | -20.32K | -20.60K | -1.10M | -183.16K | -2.39M | -5.90M | -7.97M | -11.32M | -12.44M | -16.93M | -24.25M | -28.36M | -29.06M | -28.20M | -26.55M |
| Investing Cash Flow | 0 | 0 | 0 | - | - | - | 255.75K | -2.13K | - | - | -1.83K | -40.01M | - | - | -5.00M | -5.75M |
| Financing Cash Flow | 18.49K | 20.25K | 20.47K | 1.11M | 1.68M | 1.51M | 5.26M | 10.88M | 17.30M | 11.15M | 22.90M | 120.47M | - | 13.83M | 9.97M | 33.30M |
| Capital Expenditure | - | - | - | - | - | - | - | -2.13K | - | - | -1.83K | -6.94K | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | -7.97M | - | - | -16.93M | -24.26M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Dec 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | -19,972.6% | -18,385.5% | -17,331.5% | -19,678.5% | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | -20,769.9% | -16,715.5% | -17,291.3% | -19,497.9% | - | - | - | - | - |
| ROE % | -620.0% | 110.5% | 48.0% | 213.5% | 44.4% | 99.4% | 456.9% | -49.5% | -47.3% | -40.9% | -57.3% | -52.1% | - | -32.7% | -35.8% | -55.9% | -55.4% |
| ROCE % | - | 107.5% | 42.8% | 191.4% | - | 88.1% | 508.5% | -44.4% | -45.5% | -49.5% | -48.5% | -44.6% | - | -30.4% | -37.5% | -52.0% | -44.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.79% | 215.54K | $129.32K |
| 2 | Vanguard Capital Management LLC | 0.72% | 197.36K | $118.42K |
| 3 | Miller Financial Services LLC | 0.47% | 130.00K | $78.00K |
| 4 | Citadel Advisors Llc | 0.46% | 124.91K | $74.95K |
| 5 | Jane Street Group, LLC | 0.45% | 122.84K | $73.70K |
| 6 | Vanguard Fiduciary Trust Co | 0.28% | 77.75K | $46.65K |
| 7 | Blackrock Inc. | 0.25% | 69.85K | $41.91K |
| 8 | Northern Trust Corporation | 0.23% | 62.74K | $37.65K |
| 9 | Xtx Topco Ltd | 0.22% | 59.20K | $35.52K |
| 10 | Asset Advisory Group, Inc. | 0.21% | 59.01K | $35.41K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTXR
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOVDAxTDFILU9FYTZzaUhHQjJHUXhxMEFHeHowTzMtZWZ4QnJ3ZWZ0QnVtOHk4cnp1SzdwYzQzSnd1Z3dBWGpIUHNtV2xMSWxWWWdlTHRfa1Y2QW84Z3RzejJZbHluTUZhdWFmWlA2M2kwMmdtSVowZ19ubDZYZHRsV0ZhUnpEQVFRdklzVm…
CTXR Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE15VHByQW82YVBJRTJtbDJHRmJYemVuLUNYNzR4bzRGbmF5NXdMUGJLOW43dU1nandVcmtjelk5ZUxjX3hIblFVa2s4UnlsVFo5aUpVRnlhVTViUGRZZkE?oc=5" target="_blank">CTXR Should I Buy</a> <font c…
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNSkZxSnRrbFFPWThNUElQOHU2UTRpOWZyOWFQM0d1TGFaSHZ3ZUdsSVBXelJsMjdYRFFtTEZ0d3gtNnpMUXhlbDNZSEQ4ei1RV000VXNSN1FkM0E4dDdHNTRmRlJBS1otQ0gtaGdQTHpXUmVhdDUzaXZmVFRUMHQ2ajR1OUp4Tl95amI2YT…
CTXR Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE53clE3ZlBvYVd6M0dTZ1laUVlQeUtWUEdRRXRaUUtFN0VmQXh1WDJMNmppeUxPNG9qaHgwbTVjVEdtNFVaR29xZ3pZWkpmamFJckVYRHVKd3NLNC1fbGMxRkRZb3J0RTJscFNaNVlfRE9WbDNaMnVycTdR?oc=5" target="_blank">CTX…
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPRXV6RkZiN0N5SVEtMmVMZ0JLTjVYdDNNaFIyQTkxaTlBTk5zN3FIYUNySGFVVmlFOEF1NG1kX3NiU1RTdzk3WkZFMThPNnc5VlFSUnlrVngtb1hncnVHanR1ODlIN0VsbFBLMmhidXB4bncxYUJjclFJbTZQVmxhX3c2cmdmUVZZcnMyem…
CTXR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBkN2ZIYmdpZTZQdGhHeTZ5aE1kalpveWxYT3dwOUVKanB1THE3MmdoY0JlVmljNlB6eXV2aWJ4QkEtLTRSZmc?oc=5" target="_blank">CTXR</a> <font color="#6f6f6f">Finviz</font>…
CTXR — Frequently Asked Questions
What is the current share price of Citius Pharmaceuticals, Inc. (CTXR)?
As of 2026-09-19 21:16 PDT, Citius Pharmaceuticals, Inc. (CTXR) trades at $0.60 on NasdaqCM. Its 52-week range is $0.48 to $1.82.
What is the market capitalisation of CTXR?
Citius Pharmaceuticals, Inc. (CTXR) has a market capitalisation of $16.47M on NasdaqCM.
What is the P/E ratio of CTXR?
CTXR trades at a trailing price-to-earnings (P/E) ratio of -0.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.24.
What is the return on equity (ROE) of CTXR?
CTXR has a return on equity (ROE) of -81.09%. Its return on capital employed (ROCE) is -44.79%.
Is CTXR a good stock to buy?
This page provides a data-driven analysis of Citius Pharmaceuticals, Inc. (CTXR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.